Monthly Archives: September 2009

Biotech Advances in South Dakota

Biotech Advances in South Dakota

Last week I made my first visit to our South Dakota affiliate. The South Dakota Biotech Association, formed in 2006, held its fourth annual conference on Thursday, September 17th. I began my tour on Wednesday at Hematech, Inc.   The company, headquartered in Sioux Falls, is developing cattle that can efficiently produce human antibodies.  The genetically altered cattle will be used for the production of large quantities of polyclonal antibodies.  These antibodies are expected to help Read More >

Jim's Corner  |  Leave a comment  |  Email This Post

What’s New at ImmunoVaccine Technologies

An interview with Dr. Randal Chase, President & CEO of ImmunoVaccine Technologies: Can you describe the top priorities or upcoming milestones for your company? Our first priority is to show the safety of our DepoVax™ vaccine enhancement technology in humans by taking our first product, DPX-0907 therapeutic cancer vaccine into Phase 1 clinical trials. We are anticipating filing an IND for DPX-0907 by the end of 2009 and initiating the trial in Q1 of 2010. Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: ,

A Word with Calistoga Pharmaceuticals’ CEO

An interview with Dr. Carol Gallagher, Pharm.D., CEO of Calistoga Pharmaceuticals: Can you describe the top priorities or upcoming milestones for your company? 4Q 2009: Reporting updated efficacy and safety data from the ongoing CAL-101 Phase 1 trial in patients with hematologic malignancies 1H 2010: Initiating a Phase 2 registration program for CAL-101 Initiating a Phase 2 trial evaluating CAL-263, a novel oral delta isoform-selective PI3K inhibitor, in patients with asthma Initiating a Phase 1 Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: ,

Weekly Blog Wrap Up

There’s a lot going on in the blogosphere about the world of biofuels this week. Yesterday, the World Wildlife Fund released a report,which according to NCTechnews.com, “concludes that industrial biotechnology can provide dramatic reductions in greenhouse gas emissions and provide strong progress toward a green and sustainable economy. WWF calls for increased political backing for the industry to leverage the positive environmental effects. The findings are based on peer-reviewed research from Novozymes, the world leader Read More >

Biofuels & Climate Change  |  1 Comment  |  Email This Post
Tags: , , , , , , , , , , , , , , , , , , , , ,

XOMA to Repay Goldman Sachs Loan in Full

XOMA Ltd. (Nasdaq:XOMA) announced a plan to repay its loan with Goldman Sachs Specialty Holdings, Inc. (Goldman Sachs) through a combination of funds. Payment will include proceeds from Genentech’s payment to XOMA for the buyout of its LUCENTIS(R) royalty obligation to XOMA, the sale of common stock and funds from an existing restricted cash account reserved for loan repayment. The repayment plan resolves the uncertainty about the loan that arose from the sudden and unexpected Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: ,